ELI LILLY & Co 4

Director Ralph Alvarez received a deferred stock unit award equivalent to about 113 Eli Lilly (LLY) common shares in lieu of cash compensation under a director deferral plan.

On August 17, 2026, director Ralph Alvarez elected to defer cash compensation into equity under the Lilly Directors' Deferral Plan, receiving 112.78 equivalent shares of Eli Lilly & Co common stock at an implied price of $10.4945 per unit, for an aggregate award value of approximately $1,183.16. These stock units are deferred and will be settled in shares of common stock following his separation from service. Following this award, Alvarez beneficially owns approximately 55,744.788 Eli Lilly shares directly, and an additional 758 shares are held indirectly in a trust, with the reporting person disclaiming beneficial ownership of the indirect holdings except to the extent of his pecuniary interest.

Filing Facts

CIK

59478

Ticker

LLY

Form

4

Source Type

fda

Accession

0001310215-26-000015

Alert Tier

4